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Abstract 
Introduction: Triple negative breast cancer is an aggressive breast cancer with decreased five-year 
survival, increased risk for recurrence, and higher risk for metastases. Unlike other breast cancers, it has 
no targeted treatment and has heterogeneous genetics which make classification and treatment difficult. 
Purpose: The purpose of our research was to compare triple negative breast cancer to non-triple negative 
breast cancer to identify key epidemiologic factors that might lead to improved basic science directives 
for biomarkers, treatments, and classification. 
Methods: The state cancer registry was used to provide the first West Virginia state-wide population 
evaluation of triple negative breast cancer. 
Results: The research reveals novel results that tumor grade increases exponentially with the age at 
diagnosis. 
Implications: This creates an epidemiologic foundation for future research to define whether the disease, 
access to care, biology of aging, or some other factor cause this significant finding. In addition, results 
reveal decreased use of testing that could be increased to improve biomarker identification, targeted 
treatments, and classification of triple negative breast cancer. 
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orldwide, breast cancer is a leading cause of cancer mortality in women1 
and in the U.S., invasive breast cancer impacts 12.4% of the population 
of women.2 Breast cancer is a diverse disease with five molecular 
subtypes. One type is triple negative breast cancer (TNBC), a breast cancer where 
tumors are negative for estrogen receptor, progesterone receptor, and Human 
Epidermal Growth Factor Receptor 2 overexpression.3,4 Because of its heterogeneity, 
TNBC is further divided into sub-types whose classification is still controversial with 
the most recent being the genetic profile classification.5 TNBC is an aggressive 
disease and is associated with a poorer prognosis and 5-year survival rate as there 
is a higher risk for recurrence and metastasis among affected patients.6–8 Previous 
studies have shown that the prevalence of TNBC is higher in some demographic 
groups such as women under 40 years of age and among women of black race or 
Hispanic ethnicity.6,7,9–14 
The reasons why certain demographic groups are more affected than others are 
unknown. Previous studies have proposed that obesity, diet, genetics, 
socioeconomic, and biological factors may explain differences seen among 
demographic groups in terms of TNBC. 3,6–8,11,15,16 
Because of the severity of TNBC, there has been an increased interest in investigating 
demographic, diagnostic, and prognostic factors associated with the disease not only 
nationwide, but also in West Virginia.8,9,17 The age-adjusted breast cancer mortality 
rate among women in West Virginia is the 8th highest among states.18 In addition to 
the high mortality rate, West Virginia’s population is somewhat homogenous 
compared to other states as over 94% of the population is non-Hispanic white19; 
thus, racial differences may be observed to a lesser extent. However, the population 
is of lower socioeconomic status and has greater levels of obesity compared to most 
other states.20,21 The state also has a low net migration of residents which could 
indicate that hereditary factors associated with TNBC, such as BRCA mutations, 
may remain present in the population and influence the disease’s prevalence.3,22  
To date, two studies have investigated TNBC in West Virginia.8,17 One study found 
that West Virginia patients had increased representation of advanced tumors at time 
of diagnosis.17 The other study determined that a greater proportion of women with 
TNBC were under the age of 50 and that their tumors were larger than non-TNBC 
patients; TNBC patients also were slightly more obese than non-TNBC patients.8 
However, both studies utilized unique patient populations from a university hospital 
and/or a regional medical center over 15 years ago. Thus, the purpose of this study 
was to investigate the demographic and diagnostic differences between those 
diagnosed with TNBC compared to non-TNBC utilizing more recent data from the 
state’s cancer registry, which includes all patients diagnosed with breast cancer in 
the state. The findings of this study could help inform future research in a state 
where cancer risk and mortality are high. 
W 
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The primary data source for this analysis was the West Virginia Cancer Registry, 
which is maintained by the West Virginia Department of Health and Human 
Resources in Charleston, WV. Since 1993, the registry maintains demographic and 
clinical data on individuals who are diagnosed and treated for cancer within the 
state. The registry also includes West Virginia residents who were treated outside 
the state boundary but retain a West Virginia address.23 The registry collects, codes, 
and maintains these data in accordance with the National Cancer Institute’s 
Surveillance, Epidemiology and End Results Program (SEER).24 The data are de-
identified for patient confidentiality purposes.  
Study Population 
The study population included all West Virginia women who were diagnosed with 
breast cancer (e.g., International Classification of Diseases for Oncology, Third 
Edition, codes C500–C509) from January 1, 2010, thru December 31, 2016. The 
data years 2010–2016 were selected because there were data quality concerns prior 
to 2010 and 2016 was the most recent data year available. 
Human Subject’s Protections 
This study was approved by West Virginia University’s Institutional Review Board 
(protocol #1908679407). 
Variables 
The primary dependent variable was whether an individual was diagnosed with 
TNBC (e.g., dichotomous). TNBC was defined in accordance to SEER as a breast 
cancer that is negative for estrogen receptors, progesterone receptors, and Human 
Epidermal Growth Factor Receptor 2 overexpression.24 Various independent 
variables were utilized for this analysis which included: patient’s age at diagnosis, 
race, year of diagnosis, stage of cancer at diagnosis, whether their cancer 
metastasized (binary), whether the patient’s ipsilateral axillary lymph nodes were 
implicated (binary), whether the cancer was entirely in situ (binary), tumor grade, 
whether a multigene test was performed on the patient (binary), and whether the 
patient was diagnosed with Paget’s disease of the breast (binary). The categorization 
of these variables is shown in Table 1. Race was dichotomized into white or other 
due the demographics of the state (e.g., it is primarily non-Hispanic white).19 For 
tumor grade, some patients were given a Bloom-Richardson score. Those with scores 
3–5 were considered low grade. Those with scores 6–7 or 8–9 were categorized as 
moderate and high grade, respectively.  
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Table 1. Characteristics of West Virginia women diagnosed with triple negative breast 
cancer compared to those diagnosed with other breast cancer types, 2010–2016 
(N=9100) 
 TNBC Non-TNBC Total 
Characteristic N % N % N % 
Age group       
≤40 81 7.0 318 4.0 399 4.4 
41–50 205 17.6 1055 13.3 1260 13.9 
51–60 290 24.9 1832 23.1 2122 23.3 
61–70 317 27.2 2326 29.3 2643 29.0 
≥71 273 23.4 2403 30.3 2676 29.4 
Missing 0  0    
Race       
White 1098 94.2 7665 96.7 8763 96.3 
Other 68 5.8 264 3.3 332 3.7 
Year of diagnosis       
2010 167 14.3 979 12.3 1146 12.6 
2011 171 14.7 1052 13.3 1223 13.4 
2012 161 13.8 1138 14.3 1299 14.3 
2013 172 14.8 1172 14.8 1344 14.8 
2014 151 13.0 1166 14.7 1317 14.5 
2015 185 15.9 1197 15.1 1382 15.2 
2016 159 13.6 1230 15.5 1389 15.3 
Stage at diagnosis       
Local  734 63.4 5258 66.7 5992 66.2 
Regional direct 26 2.3 151 1.9 177 2.0 
Regional lymph 255 22.0 1817 23.0 2072 22.9 
Direct and lymph 49 4.2 214 2.7 263 2.9 
Distant 94 8.1 448 5.7 542 6.0 
Unknown 8  46  54  
Metastasis       
Yes 73 6.9 389 5.4 7867 94.5 
No 993 93.1 6874 94.6 462 5.6 
Missing 100  671  771  
Node involvement       
Yes 283 29.8 1985 29.6 2268 29.6 
No 668 70.2 4730 70.4 5398 70.4 
Missing 215  1219  1434  
In situ       
Yes 3 0.3 15 0.2 18 0.2 
No 1093 99.7 7599 99.8 8692 99.8 
Missing 70  320  390  
Tumor grade       
Low 60 5.6 2164 29.2 2224 26.3 
Moderate 226 21.3 3571 48.2 3797 44.8 
High 777 73.1 1670 22.6 2447 28.9 
Missing 103  529  632  
Multigene test 
performed 
      
Yes 49 5.8 1759 28.8 1808 26.0 
No 802 94.2 4346 71.2 5148 74.0 
Missing 315  1829    
Paget’s       
Yes 6 0.7 62 1.0 68 1.0 
No 900 99.3 5960 99.0 6860 99.0 
Missing 260  1912  2172  
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ANALYSES 
Because the objective of this study was to compare the characteristics of women in 
West Virginia who were diagnosed with TNBC to other types of breast cancers, 
several analyses were conducted. The demographic and diagnostic characteristics 
between those diagnosed with and without TNBC were compared via frequencies and 
percentages. In order to determine which variables were associated with TNBC in 
patients, both binary and multivariable logistic regression analyses were conducted; 
these types of models were chosen because the outcome was dichotomous.25 
Unadjusted (i.e., binary) models were ran between each independent variable and 
the outcome. All multivariable models were adjusted for age group, race, and year of 
diagnosis. (However, it should be noted that the multivariable model for age group 
was only adjusted for year and race and the multivariable model for race was only 
adjusted for year and age group). These models were adjusted for these variables 
because there are known differences with TNBC diagnoses among different age 
groups and races in other clinical populations.9 Year was also adjusted for because 
of the increasing awareness of TNBC in the literature overtime which could 
potentially influence diagnoses.26 A third set of multivariable models were ran to 
investigate potential effect measure modification. These models contained the same 
variables in the first multivariable model but also included two interaction terms; 
there was one interaction term between the independent variable of interest and age 
group and another interaction term between the independent variable of interest and 
race.27 All data management and statistical analyses were conducted in SAS/STAT 
software version 9.4 (Cary, NC) with two-sided significance level α=0.05.  
RESULTS 
Nearly 13% of the women diagnosed with breast cancer in West Virginia had TNBC 
(Table 1). While nearly 60% of all breast cancer patients were over 60 years of age, a 
slightly larger proportion of women ≤40 years of age were diagnosed with TNBC (7%) 
compared to those with non-TNBC (4%). In regard to race, there was an increased 
percentage of non-whites (6%) diagnosed with TNBC compared to the non-TNBC 
group (3%). The stage of cancer at diagnosis confirmed a more aggressive cancer in 
TNBC with (4.2%) involving direct and lymph nodes compared to non-TNBC (2.7%) 
and a distant cancer in TNBC (8.1%) compared to distant cancer in non-TNBC (5.7%) 
at time of diagnosis. Metastasis was higher in TNBC (6.9%) compared to non-TNBC 
(5.4%). Tumor grade differed in TNBC patients with 73.1% in high grade compared 
to only 22.6% high grade in non-TNBC. While only 26% of patients with breast 
cancer received a multigene test, only 6% of TNBC patients received it compared to 
29% of non-TNBC patients.  
Table 2 shows the association between TNBC and demographic and diagnostic 
criteria. After adjusting for race and year, the odds of TNBC diagnoses in women ≤40 
was 2.2 times greater than the odds of TNBC in women ≥71 years of age. The odds 
of a TNBC diagnosis in non-whites was 71% higher than the odds of TNBC in whites 
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after adjusting for age and year. Additionally, it appeared that TNBC was associated 
with higher tumor grades. The odds of TNBC was 16 times greater in high tumor 
grades than the odds of TNBC in women with low tumor grades at time of diagnosis 
after adjusting for age, race, and year. Yet, the odds of a TNBC diagnoses was 86% 
lower among those receiving a multigene test compared to the odds of a TNBC 
diagnoses among those not receiving a multigene test. 
Table 2.  The association between triple negative breast cancer (TNBC) and 
demographic and diagnostic criteriaa 




Model 1 Model 2 
Characteristic   OR 95% CI OR 95% CI 
Age group       
≤40 399 20.3 2.24 1.70, 2.95 2.19 1.67, 2.88 
41-50 1260 16.3 1.71 1.41, 2.08 1.68 1.38, 2.05 
51-60 2122 13.7 1.39 1.17,1.66 1.38 1.15, 1.64 
61-70 2643 12.0 1.20 1.01, 1.42 1.20 1.01, 1.42 
≥71 2676 10.2 1.00 Referent 1.00 Referent 
Race       
White 8763 12.5 1.00 Referent 1.00 Referent 
Other 332 20.5 1.80 1.38, 2.37 1.71 1.30, 2.26 
Node Involvement       
Yes 2268 12.5 1.01 0.87, 1.17 0.95 0.81, 1.10 
No 5398 12.4 1.00 Referent 1.00 Referent 
In situ       
Yes 18 16.7 1.39 0.40, 4.81 1.58 0.46, 5.49 
No 8692 12.6 1.00 Referent 1.00 Referent 
Tumor grade       
Low 2224 2.7 1.00 Referent 1.00 Referent 
Moderate 3797 6.0 2.28 1.71, 3.05 2.27 1.70, 3.03 




Metastasis       
Yes 462 15.8 1.30 1.00, 1.68 1.29 0.99, 1.67 
No 7867 12.6 1.00 Referent 1.00 Referent 
Multigene       
Yes 1808 2.7 0.15 0.11, 0.20 0.14 0.11, 0.19 
No 5148 15.6 1.00 Referent 1.00 Referent 
Paget       
Yes 68 8.8 0.64 0.28, 1.49 0.66 0.28, 1.53 
No 6860 13.1 1.00 Referent 1.00 Referent 
Abbreviations: TNBC=triple negative breast cancer 
Model 1 is a binary model between the characteristic and TNBC status (yes/no) as the 
outcome.  Model 2 is the adjusted model.  All adjusted models, except age group and 
race, were adjusted for age group, race, and year of diagnosis.  The multivariable model 
for age group was adjusted for year and race.  The multivariable model for race was 
adjusted for year and age group. 
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Age was an effect modifier of the relationship between TNBC diagnoses and tumor 
grade (Table 3). After adjusting for both year and race, the odds of TNBC dramatically 
increased with more severe tumor grades over the age groups. A female under the 
age of 40 diagnosed with TNBC had 5 times greater odds of having a high tumor 
grade compared to the odds of a woman in the same age group diagnosed with TNBC 
having a low- grade tumor. However, the odds of TNBC for a female ≥71 years of age 
to be high grade stage was nearly 22 times greater than the odds of a TNBC diagnoses 
for a female in the same age group having a low-grade tumor.  
 
Table 3. Effect measure modification of tumor grade 
by age group among patients diagnosed with triple 
negative breast cancer vs. regular breast cancera 
 Model 1 
Grade by Age 
group 
OR 95% CI 
≤40   
Low 1.00 Referent 
Moderate 1.16 0.36, 3.73 
High 5.41 1.85, 15.80 
41-50   
Low 1.00 Referent 
Moderate 1.12 0.55, 2.27 
High 10.48 5.67, 19.39 
51-60   
Low 1.00 Referent 
Moderate 1.89 1.03, 3.46 
High 14.61 8.37, 25.52 
61-70   
Low 1.00 Referent 
Moderate 2.54 1.46, 4.42 
High 20.17 11.96, 34.02 
≥71   
Low 1.00 Referent 
Moderate 3.64 2.04, 6.50 
High 21.73 12.42, 38.03 
a: Model was adjusted for year and race.  The outcome 
was whether the patient was diagnosed for triple 
negative breast cancer vs. regular breast cancer.  The 
primary independent variable was tumor grade at 
diagnosis, which is stratified by age group 
 
Age was also an effect modifier of the relationship between TNBC diagnosis and 
multigene test conductance (Table 4). It appears that the conductance of the 
multigene test decreases with age. While there were no differences in women ≤40, 
after adjusting for year and race, the odds of TNBC diagnoses among those aged 41–
50 years is 75% lower if multigene test is conducted compared to the odds of a TNBC 
diagnoses among women of the same age who do not receive the multigene signature 
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test. However, the odds of TNBC diagnoses among those aged ≥71 years is 88% lower 
if multigene test is conducted compared to the odds of a TNBC diagnoses among 
women of the same age who do not receive the multigene signature test. 
 
Table 4. Effect measure modification of multigene test 
conductance by age group among patients diagnosed with 
triple negative breast cancer vs. regular breast cancera 
 Model 1 
Multigene test by age 
group 
OR 95% CI 
≤40   
Yes  0.52 0.24, 1.13 
No 1.00 Referent 
41-50   
Yes  0.25 0.15, 0.43 
No 1.00 Referent 
51-60   
Yes  0.05 0.02, 0.11 
No 1.00 Referent 
61-70   
Yes  0.11 0.07, 0.19 
No 1.00 Referent 
≥71   
Yes  0.12 0.04, 0.32 
No 1.00 Referent 
a: Model was adjusted for year and race.  The outcome was whether 
the patient was diagnosed for triple negative breast cancer vs. 
regular breast cancer.  The primary independent variable was 
whether the patient received multigene therapy, which is stratified 




Several important findings were discovered as a result of this analysis. First, trends 
in TNBC diagnoses typically seen in other studies were also seen in West Virginia. 
Second, TNBC diagnosis and tumor grade varied by age, which is a novel finding. 
Third, while multigene testing was infrequently performed among all breast cancer 
patients, there was an inverse relationship between age and multigene conductance 
among TNBC patients specifically. These are important findings especially when 
considering the previous literature indicating delayed diagnoses of breast cancer 
among West Virginia patients.17 This generates an imperative to improve early 
diagnosis, treatment planning, and cancer typing.  
In relation to the current literature, the findings were consistent with those of 
previous nationwide studies. The prevalence of TNBC in West Virginia was 13%, 
which is similar to the nationwide prevalence of 13%.9 Similarly, a there was a larger 
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portion of patients under 40 years old within the TNBC population when compared 
to the non-TNBC population. Also consistent with the literature was the increased 
percentage of non-whites in the TNBC population despite a 94% white non-Hispanic 
population prevalence in West Virginia,9,19 and confirmation of TNBC’s aggressive 
form and increased risk for metastasis. However, the majority of TNBC patients were 
older adults and there was a significant increased risk for high grade tumor in older 
patients at time of diagnoses with TNBC.  
The novel finding concerning TNBC diagnosis and tumor grade variation by age 
provides opportunity for future research. The numbers are significant and may be 
due to biological reasons such as decreased physiologic response with aging, access 
to care, a feature of the TNBC disease, or some other factor. The finding warrants 
additional investigation, perhaps using national data.  
Multigene testing was not performed frequently, especially in TNBC patients, and 
the test's frequency decreased with patient age. The cost, difficulty of coverage for 
testing, and limitations of many tests in healthcare make this result unsurprising. 
However, the increasing benefit of genetic and epigenetic research as well as 
improvements to the multigene test itself may indicate opportunity for change. The 
data of this project indicates there may be opportunity for improved patient 
outcomes with future research to identify barriers to its clinical use.  
New multigene signature testing provides American Joint Committee on Cancer 
(AJCC) staging and molecular subtyping, both valuable tools for improving our 
ability to classify cancer types and generate research data for identifying targeted 
treatment. Research by Lehman et al discovered from retrospective pretreatment 
biopsies that prediction regarding neoadjuvant response to therapy was not only 
possible but indicated the probability that there were both chemotherapeutic 
sensitive and chemotherapeutic insensitive subtypes in TNBC.28 In addition, 
research from multiple sources of basic science have linked cancer from the breast 
with the upregulation of a gene, protein, or general pathway.29 For example, in 2009, 
there was documentation of upregulation of hexokinase 2 in breast cancer brain 
metastasis linked with poor prognosis.30 Thus, there is indication that multigene 
testing could assist evaluation of tumor to aid typing and prognosis for future breast 
cancer patients. Multigene signature testing alone is not the complete answer to 
identify targeted treatment, stratify risks, and improve outcomes of clinical 
applications. However, improved use of this tool in conjunction with other clinical 
tools and parameters may improve patient stratification for treatment and lead to 
data for identifying targeted treatments.  
Limitations 
While this study highlighted some important differences between TNBC and non-
TNBC in West Virginia, it is not without limitation. One of the inherent limitations 
of this study was that only a limited number of variables were available for analyses. 
Some diagnostic variables, such as response to neoadjuvant therapy or risk of 
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recurrence, contained a large amount of missing data and could not be analyzed. 
Also, variables which could impact both the diagnoses and prognoses of patients, 
such as patient obesity status, insurance coverage, patient preference, 
comorbidities, or access to care, were unavailable, and could be potential 
confounding factors. 
CONCLUSION 
This research is broad in its evaluation by use of the entire West Virginia breast 
cancer registry data. It is unique in its analysis to identify present evidence of TNBC 
disease in West Virginia and its discussion of testing practice to raise pertinent 
questions. It is translational in its combination of basic science and clinical 
application perspective.  
Triple negative breast cancer in West Virginia is similar to the nation in its 
demographic evidence and its aggressive nature. This new finding of TNBC diagnosis 
and tumor grade variation by age urges future research. While the discussion of 
multigene signature testing reflects opportunity to evaluate policy and practice for 
its use. Increased efforts are being made to extend multigene testing to whole genome 
evaluation of tumors to bolster the information gleaned from tumors.31 Therefore, 
increased use of the multigene signature tool may improve our ability to develop 
biomarkers for early identification of disease, targeted treatment, and response to 
therapy. Evaluation regarding this finding of exponential increase of high-grade 
tumor findings with increased age at diagnosis and evaluation of constraints 
impacting the use of the multigene signature test could be beneficial epidemiologic 
ventures for future research. This research supports the need for increased focus on 
tumor evaluation and early diagnosis to improve outcomes for patients. 
 
SUMMARY BOX  
What is already known about this topic?  Triple negative breast cancer is known to be an 
aggressive breast cancer subtype with a worse prognosis when compared to other breast 
cancer types. 
What is added by this report?  This report is the first evaluation and analysis of TNBC using 
data representative of all of West Virginia. This report identifies a new finding of TNBC 
diagnosis and tumor grade variation by age in this Appalachian population. This report also 
identifies variability in the use of multigene testing in the TNBC population. 
What are the implications for future research?  Implications for future research are: (1) to 
identify if this new tumor grade finding is unique to the West Virginia Appalachian population 
by comparison analysis with nationwide data, and (2) to evaluate policy and practice of 
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